RayKnowChina Research Map
Shortlist

ShanghaiShanghai Jiao Tong University School of Medicine

Shanghai Sixth People's Hospital

上海市第六人民医院

Listed for 20 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanghai Sixth People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌0 papers led
  3. Hepatocellular carcinoma肝细胞癌27 papers led
  4. Stomach cancer胃癌21 papers led
  5. Chordoma脊索瘤0 papers led
  6. Osteosarcoma骨肉瘤35 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Neuroblastoma神经母细胞瘤4 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤1 paper led
  11. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  13. Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
  14. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  15. Alport syndromeAlport 综合征0 papers led
  16. IgA nephropathyIgA 肾病0 papers led
  17. Osteogenesis imperfecta成骨不全症7 papers led
  18. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  19. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  20. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  2. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImmunotherapy
Departments in papersRadiation oncologyENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led no English-language PubMed papers on oesophageal squamous cell carcinoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
More papers found outside PubMed (not counted)16
  1. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  2. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  3. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  5. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  9. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  10. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  11. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  12. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  13. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  14. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  15. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  16. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 27 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 6620232024: 2220242025: 442025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led27
  1. miR-32-5p suppresses the progression of hepatocellular carcinoma by regulating the GSK3β/NF-κB signaling.2025Acta biochimica et biophysica SinicaFree full text
  2. Bi-Regional Machine Learning Radiomics Based on CT Noninvasively Predicts LOX Expression Level and Overall Survival in Hepatocellular Carcinoma.2025Cancer medicineFree full text
  3. Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism.2025Cell metabolism
  4. Integrated single-cell RNA-seq analysis reveals that EZH2 regulates the MIF-CD74 axis to modulate T cell activation and exhaustion in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  5. Novel Chemo-Photothermal Therapy in Hepatic Cancer Using Gemcitabine-Loaded Hyaluronic Acid Conjugated MoS2/ZnO Nanocomposites.2024Applied biochemistry and biotechnology
  6. Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis.2024Journal of experimental & clinical cancer research : CRFree full text
  7. Multi-cohort validation study of a four-gene signature for risk stratification and treatment response prediction in hepatocellular carcinoma.2023Computers in biology and medicine
  8. Exosomal proteomics identifies RAB13 as a potential regulator of metastasis for HCC.2023Hepatology communicationsFree full text
  9. The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  10. Short- and Long-Term Outcomes in Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Elderly Patients: A Systematic Review and Meta-Analysis.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma.2023Journal of nanobiotechnologyFree full text
  12. Restratification of Advanced Hepatocellular Carcinoma to Identify Patients Sensitive to Transarterial Chemoembolization.2023RadiologyFree full text
  13. MELD‑Na and short-term outcome of patients with ruptured hepatocellular carcinoma receiving transarterial embolization.2022Abdominal radiology (New York)
  14. Extracellular Vesicle-Encapsulated MicroRNA-375 from Bone Marrow-Derived Mesenchymal Stem Cells Inhibits Hepatocellular Carcinoma Progression through Regulating HOXB3-Mediated Wnt/β-Catenin Pathway.2022Analytical cellular pathology (Amsterdam)Free full text
  15. Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: A meta-analysis.2022Clinics and research in hepatology and gastroenterology
  16. Re: Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial: The jury is still out.2022European journal of cancer (Oxford, England : 1990)
  17. Iodized oil CT-guided radiofrequency ablation for hepatocellular carcinoma within Milan criteria.2022Hepatology international
  18. No-Touch Radiofrequency Ablation for Small Hepatocellular Carcinoma.2022Radiology
  19. Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling.2022TheranosticsFree full text
  20. Outcomes of adolescent and young patients with hepatocellular carcinoma after curative liver resection: a retrospective study.2022World journal of surgical oncologyFree full text
  21. Long non-coding RNA FEZF1-AS1 promotes the proliferation and metastasis of hepatocellular carcinoma via targeting miR-107/Wnt/β-catenin axis.2021AgingFree full text
  22. Up-regulated RFC2 predicts unfavorable progression in hepatocellular carcinoma.2021HereditasFree full text
  23. Long non-coding RNA ZEB1-AS1 promotes proliferation and metastasis of hepatocellular carcinoma cells by targeting miR-299-3p/E2F1 axis.2021Journal of biochemistry
  24. Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer.2021Journal of cellular and molecular medicineFree full text
  25. Comprehensive analysis of N6 -methyladenosine-related long non-coding RNAs for prognosis prediction in liver hepatocellular carcinoma.2021Journal of clinical laboratory analysisFree full text
  26. CEUS examination of the outcome of radiofrequency ablation of canine prostate lesions.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  27. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.2021Protein & cellFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)Status unknownNCT06023147Study siteN/AStart 2023-09
  3. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  4. Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCCStatus unknownNCT05339321Study sitePhase 1Start 2021-04
  5. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  6. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  7. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  8. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 3320222023: 3320232024: 6620242025: 222025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncology

Over half of these papers are lab or animal studies.

Papers it led21
  1. The comparison of post-proximal gastrectomy digestive tract reconstruction methods.2025BMC surgeryFree full text
  2. A nomogram prediction model for the risk of intra-abdominal infection after endoscopic full-thickness resection of gastric submucosal tumors.2025Biomedical engineering onlineFree full text
  3. Helicobacter Pylori-Enhanced hnRNPA2B1 Coordinates with PABPC1 to Promote Non-m6A Translation and Gastric Cancer Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance.2024Anti-cancer drugsRCTFree full text
  5. Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.2024British journal of cancerFree full text
  6. CircUGGT2 downregulation by METTL14-dependent m6A modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186-3p/MAP3K9 axis.2024Pharmacological research
  7. LncRNA FAM83H-AS1 Contributes to the Radio-resistance and Proliferation in Liver Cancer through Stability FAM83H Protein.2024Recent patents on anti-cancer drug discovery
  8. Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab.2024The FEBS journal
  9. Overexpression of RAB31 in gastric cancer is associated with released exosomes and increased tumor cell invasion and metastasis.2023Cancer medicine
  10. m6A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.2023Cellular signalling
  11. A unique case of well-differentiated gastric-type adenocarcinoma coexisting with a gastric adenocarcinoma of the fundic gland in a Helicobacter pylori-uninfected stomach.2023EndoscopyFree full text
  12. Bile Acid-Microbiome Interaction Promotes Gastric Carcinogenesis.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  13. A rare helicobacter pylori infection-negative early gastric cancer in a young man with primary hypertrophic osteoarthropathy.2022Endoscopy
  14. METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis.2022Molecular cancerFree full text
  15. Retrospective analysis of the clinical effects of endoscopic mucosal dissection on treatment of early esophagogastric precancerous lesions.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  16. Hypoxia-induced FOXO4/LDHA axis modulates gastric cancer cell glycolysis and progression.2021Clinical and translational medicineFree full text
  17. SNHG10 Promotes Cell Proliferation and Migration in Gastric Cancer by Targeting miR-495-3p/CTNNB1 Axis.2021Digestive diseases and sciences
  18. Placenta-specific protein 1 promotes cell proliferation via the AKT/GSK-3β/cyclin D1 signaling pathway in gastric cancer.2021IUBMB life
  19. Melatonin indirectly decreases gastric cancer cell proliferation and invasion via effects on cancer-associated fibroblasts.2021Life sciences
  20. CircPTK2 inhibits the tumorigenesis and metastasis of gastric cancer by sponging miR-134-5p and activating CELF2/PTEN signaling.2021Pathology, research and practice
  21. Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways.2021Pathology, research and practice
All its trials on ClinicalTrials.gov, any status2
  1. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  2. Apatinib Dose Titration in Advanced or Metastatic Gastric CancerCompletedNCT02764268Study siteN/AStart 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Clinicopathological features of notochordal tumors: a study of 48 cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 35 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.6%.

Papers led
35
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 6620222023: 2220232024: 121220242025: 662025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07596693

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  2. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRheumatology & immunologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led35
  1. Adipocytes Promote Cisplatin Resistance through Secreting A1BG and Regulating NAMPT/PARP1 Axis-Mediated DNA Repair in Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Ultrasound-Responsive 4D Bioscaffold for Synergistic Sonopiezoelectric-Gaseous Osteosarcoma Therapy and Enhanced Bone Regeneration.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. Role of arachidonic acid metabolism in osteosarcoma prognosis by integrating WGCNA and bioinformatics analysis.2025BMC cancer
  4. Marsdenia tenacissima extract accelerates ferroptosis of osteosarcoma cells by upregulating HO-1 and activating mitophagy.2025Journal of ethnopharmacology
  5. Identification and verification of a polyamine metabolism-related gene signature for predicting prognosis and immune infiltration in osteosarcoma.2025Journal of orthopaedic surgery and research
  6. Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models.2025Scientific reports
  7. Tongguanteng injection exerts anti-osteosarcoma effects through the ER stress-associated IRE1/CHOP pathway.2024BMC complementary medicine and therapies
  8. Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma.2024BMC complementary medicine and therapies
  9. Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway.2024Cancer chemotherapy and pharmacology
  10. Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis.2024Cellular oncology (Dordrecht, Netherlands)
  11. GNAS, not a Highly Mutated Gene, Has Prognostic Significance and Carcinogenic Effects in Osteosarcoma.2024Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  12. Peritoneal Metastasis of Osteosarcoma in 99m Tc-MDP SPECT/CT Imaging.2024Clinical nuclear medicine
  13. Alterations in Serum Lipids and Lipoproteins Induced by Neoadjuvant Chemotherapy in Patients with Osteosarcoma around the Knee Joint: A Retrospective Analysis.2024Current medical science
  14. High expression of DEC2 distinguishes chondroblastic osteosarcoma and promotes tumour growth by activating the VEGFC/VEGFR2 signalling pathway.2024Journal of cellular and molecular medicine
  15. Cargo-eliminated osteosarcoma-derived small extracellular vesicles mediating competitive cellular uptake for inhibiting pulmonary metastasis of osteosarcoma.2024Journal of nanobiotechnology
  16. Modulating tumor-associated macrophage polarization by anti-maRCO mAb exerts anti-osteosarcoma effects through regulating osteosarcoma cell proliferation, migration and apoptosis.2024Journal of orthopaedic surgery and research
  17. Osteitis in long bones of SAPHO syndrome mimicking osteosarcoma.2024Rheumatology (Oxford, England)
  18. Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  19. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  20. Ebastine exerts antitumor activity and induces autophagy by activating AMPK/ULK1 signaling in an IPMK-dependent manner in osteosarcoma.2023International journal of biological sciences
  21. Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signalling pathway.2022Acta pharmaceutica (Zagreb, Croatia)
  22. Novel 1,3,5-triazine-nicotinohydrazide derivatives induce cell arrest and apoptosis in osteosarcoma cancer cells and inhibit osteosarcoma in a patient-derived orthotopic xenograft mouse model.2022Chemical biology & drug design
  23. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients.2022Clinical and translational medicine
  24. Deduction of CDC42EP3 suppress development and progression of osteosarcoma.2022Experimental cell research
  25. FAT1 and MSH2 Are Predictive Prognostic Markers for Chinese Osteosarcoma Patients Following Chemotherapeutic Treatment.2022Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  26. Identification of Common Oncogenic Genes and Pathways Both in Osteosarcoma and Ewing's Sarcoma Using Bioinformatics Analysis.2022Journal of immunology research
  27. W-Doped TiO2 Nanorods for Multimode Tumor Eradication in Osteosarcoma Models under Single Ultrasound Irradiation.2021ACS applied materials & interfaces
  28. Impact of Secondary Aneurysmal Bone Cysts on Survival of Patients with Enneking Stage IIB Extremity Osteosarcoma: A Propensity Score Matching Analysis.2021Annals of surgical oncology
  29. Chitooligosaccharides inhibit tumor progression and induce autophagy through the activation of the p53/mTOR pathway in osteosarcoma.2021Carbohydrate polymers
  30. Alpha-(1,6)-fucosyltransferase (FUT8) affects the survival strategy of osteosarcoma by remodeling TNF/NF-κB2 signaling.2021Cell death & disease
  31. Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.2021Cell death & disease
  32. Deregulation of CLTC interacts with TFG, facilitating osteosarcoma via the TGF-beta and AKT/mTOR signaling pathways.2021Clinical and translational medicine
  33. Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden.2021Frontiers in endocrinology
  34. Role of PRPS2 as a prognostic and therapeutic target in osteosarcoma.2021Journal of clinical pathology
  35. Clinical significance of indeterminate pulmonary nodules on the survival of 364 patients with nonmetastatic, high-grade, localized osteosarcoma: A 12-year retrospective cohort study.2021Journal of surgical oncology
Earlier papers (2016–2020)56
  1. EWSAT1 Acts in Concert with Exosomes in Osteosarcoma Progression and Tumor-Induced Angiogenesis: The "Double Stacking Effect".2020Advanced biosystems
  2. Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy.2020BioMed research international
  3. Long noncoding RNA OIP5-AS1 mediates resistance to doxorubicin by regulating miR-137-3p/PTN axis in osteosarcoma.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Is increased symptom interval associated with advanced stage and poorer outcome? A prospective multicenter study of 220 patients with osteosarcoma around the knee.2020Cancer epidemiology
  5. N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1.2020EBioMedicine
  6. CDKL3 promotes osteosarcoma progression by activating Akt/PKB.2020Life science alliance
  7. DDX11-AS1 contributes to osteosarcoma progression via stabilizing DDX11.2020Life sciences
  8. Organoid culture system for patient-derived lung metastatic osteosarcoma.2020Medical oncology (Northwood, London, England)
  9. Piceatannol suppresses proliferation and induces apoptosis by regulation of the microRNA‑21/phosphatase and tensin homolog/protein kinase B signaling pathway in osteosarcoma cells.2020Molecular medicine reports
  10. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.2020Nature communications
  11. A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.2020Scientific reports
  12. Engineering 2D Mesoporous Silica@MXene-Integrated 3D-Printing Scaffolds for Combinatory Osteosarcoma Therapy and NO-Augmented Bone Regeneration.2020Small (Weinheim an der Bergstrasse, Germany)
  13. Cancer cell membrane coated silica nanoparticles loaded with ICG for tumour specific photothermal therapy of osteosarcoma.2019Artificial cells, nanomedicine, and biotechnology
  14. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.2019BMC cancer
  15. miR-23b-3p suppressing PGC1α promotes proliferation through reprogramming metabolism in osteosarcoma.2019Cell death & disease
  16. Integrated analysis of transcriptome-wide m6A methylome of osteosarcoma stem cells enriched by chemotherapy.2019Epigenomics
  17. Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?2019European radiology
  18. MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen.2019International journal of oncology
  19. Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1.2019Journal of molecular medicine (Berlin, Germany)
  20. Monitoring Response to Neoadjuvant Chemotherapy of Primary Osteosarcoma Using Diffusion Kurtosis Magnetic Resonance Imaging: Initial Findings.2019Korean journal of radiology
  21. SKA1 induces de novo MTX-resistance in osteosarcoma through inhibiting FPGS transcription.2019The FEBS journal
  22. Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc.2018Cancer biology & therapy
  23. 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Multiple Extraskeletal Osteosarcomas.2018Clinical nuclear medicine
  24. Myokines related to leukocyte recruitment are down-regulated in osteosarcoma.2018International journal of medical sciences
  25. Downregulation of SOX3 leads to the inhibition of the proliferation, migration and invasion of osteosarcoma cells.2018International journal of oncology
  26. EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.2018Journal of experimental & clinical cancer research : CR
  27. pH-responsive mesoporous ZSM-5 zeolites/chitosan core-shell nanodisks loaded with doxorubicin against osteosarcoma.2018Materials science & engineering. C, Materials for biological applications
  28. Magnetic Mesoporous Calcium Sillicate/Chitosan Porous Scaffolds for Enhanced Bone Regeneration and Photothermal-Chemotherapy of Osteosarcoma.2018Scientific reports
  29. Elevated expression of serine/threonine phosphatase type 5 correlates with malignant proliferation in human osteosarcoma.2017Acta biochimica Polonica
  30. Geraniin inhibits migration and invasion of human osteosarcoma cancer cells through regulation of PI3K/Akt and ERK1/2 signaling pathways.2017Anti-cancer drugs
  31. Baicalin inhibits human osteosarcoma cells invasion, metastasis, and anoikis resistance by suppressing the transforming growth factor-β1-induced epithelial-to-mesenchymal transition.2017Anti-cancer drugs
  32. Bioinformatics prediction of miR-30a targets and its inhibition of cell proliferation of osteosarcoma by up-regulating the expression of PTEN.2017BMC medical genomics
  33. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro.2017Biological research
  34. Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/β-Catenin Signaling Pathway.2017Calcified tissue international
  35. TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.2017European review for medical and pharmacological sciences
  36. Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth.2017International journal of biological sciences
  37. The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3β/β-Catenin/cyclinD1 Signaling Pathway.2017International journal of biological sciences
  38. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.2017International journal of oncology
  39. Sex-determining region Y-box protein 3 induces epithelial-mesenchymal transition in osteosarcoma cells via transcriptional activation of Snail1.2017Journal of experimental & clinical cancer research : CR
  40. CNOT1 cooperates with LMNA to aggravate osteosarcoma tumorigenesis through the Hedgehog signaling pathway.2017Molecular oncology
  41. Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.2017Oncology reports
  42. SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway.2017Oncology reports
  43. Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.2017Oncotarget
  44. Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis.2017PloS one
  45. Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients.2017Scientific reports
  46. CSE1L interaction with MSH6 promotes osteosarcoma progression and predicts poor patient survival.2017Scientific reports
  47. [Sensitivity of doxorubicin-resistant osteosarcoma cells to doxorubicin regulated by long non-coding RNA NR_036444].2017Zhonghua zhong liu za zhi [Chinese journal of oncology]
  48. Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression.2016Acta pharmacologica Sinica
  49. Symptom interval of osteosarcoma around the knee joint: an analysis of 82 patients of a single institute.2016European journal of cancer care
  50. High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis.2016International journal of molecular sciences
  51. Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells.2016Molecular medicine reports
  52. Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma.2016Molecular medicine reports
  53. Clinical characteristics and prognoses of six patients with multicentric giant cell tumor of the bone.2016Oncotarget
  54. The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy.2016Oncotarget
  55. Prognostic value of inflammation-based scores in patients with osteosarcoma.2016Scientific reports
  56. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].2016Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status6
  1. Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in OsteosarcomaCompletedNCT06562673Lead sponsorPhase 1/Phase 2Start 2024-12
  2. KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)RecruitingNCT07596693Study sitePhase 1Start 2025-12
  3. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06
  4. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Study sitePhase 1/Phase 2Start 2023-01
  5. Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)CompletedNCT05277480Study sitePhase 2Start 2022-03
  6. A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade OsteosarcomaStatus unknownNCT03676985Study sitePhase 1/Phase 2Start 2018-10

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 4 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyENT / head & neck surgeryRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

4 hospitals in Shanghai for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisRelapse preventionImaging
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shanghai for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 7 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 7.1%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 222025

6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07557446

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led7
  1. Hearing loss in Chinese osteogenesis imperfecta patients.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate.2025Frontiers in endocrinology
  3. Echocardiographic abnormalities and joint hypermobility in Chinese patients with Osteogenesis imperfecta.2024Orphanet journal of rare diseases
  4. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.2024Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  5. Comparing Clinical and Genetic Characteristics of De Novo and Inherited COL1A1/COL1A2 Variants in a Large Chinese Cohort of Osteogenesis Imperfecta.2022Frontiers in endocrinology
  6. Clinical and genetic analysis in 185 Chinese probands of osteogenesis imperfecta.2021Journal of bone and mineral metabolism
  7. Novel mutations in BMP1 result in a patient with autosomal recessive osteogenesis imperfecta.2021Molecular genetics & genomic medicine
Earlier papers (2016–2020)3
  1. Novel mutations of the SERPINF1 and FKBP10 genes in Chinese families with autosomal recessive osteogenesis imperfecta.2018International journal of molecular medicine
  2. Novel mutations in the SEC24D gene in Chinese families with autosomal recessive osteogenesis imperfecta.2017Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  3. Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61 Chinese patients with osteogenesis imperfecta.2016Molecular medicine reports
All its trials on ClinicalTrials.gov, any status2
  1. A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)RecruitingNCT07557446Study sitePhase 2Start 2026-07
  2. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingNCT05972551Study sitePhase 3Start 2024-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

上海市第六人民医院

Shanghai Sixth People's Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Qingdao Sixth People's Hospital; Sixth People's Hospital of Shenyang; Shanghai Jiaotong University Affiliated Sixth People's Hospital; Sixth People's Hospital of Chengdu; Sixth People's Hospital of Qingdao; Shanghai Jiao Tong University Affiliated with Sixth People's Hospital; Jinshan Branch of Shanghai Sixth People's Hospital

Suggest a correctionDownload the data